K
Kentaro Yamazaki
Researcher at Royal Melbourne Hospital
Publications - 246
Citations - 5167
Kentaro Yamazaki is an academic researcher from Royal Melbourne Hospital. The author has contributed to research in topics: Colorectal cancer & Bevacizumab. The author has an hindex of 26, co-authored 191 publications receiving 3860 citations.
Papers
More filters
Journal ArticleDOI
Randomized Trial of TAS-102 for Refractory Metastatic Colorectal Cancer
Robert J. Mayer,Eric Van Cutsem,Alfredo Falcone,Takayuki Yoshino,Rocio Garcia-Carbonero,Nobuyuki Mizunuma,Kentaro Yamazaki,Yasuhiro Shimada,Josep Tabernero,Yoshito Komatsu,Alberto Sobrero,Eveline Boucher,Marc Peeters,Ben Tran,Heinz-Josef Lenz,Alberto Zaniboni,Howard S. Hochster,James M. Cleary,Hans Prenen,Fabio Benedetti,Hirokazu Mizuguchi,Lukas Makris,Masanobu Ito,Atsushi Ohtsu +23 more
TL;DR: In patients with refractory colorectal cancer, TAS-102, as compared with placebo, was associated with a significant improvement in overall survival, and this phase 3 trial was the first to report this result.
Journal ArticleDOI
Ramucirumab versus placebo in combination with second-line FOLFIRI in patients with metastatic colorectal carcinoma that progressed during or after first-line therapy with bevacizumab, oxaliplatin, and a fluoropyrimidine (RAISE): A randomised, double-blind, multicentre, phase 3 study
Josep Tabernero,Takayuki Yoshino,Allen Lee Cohn,Radka Obermannova,György Bodoky,Rocio Garcia-Carbonero,Tudor Ciuleanu,David Craig Portnoy,Eric Van Cutsem,Axel Grothey,Jana Prausová,Pilar García-Alfonso,Kentaro Yamazaki,Philip Clingan,Sara Lonardi,Tae Won Kim,Lorinda Simms,Shao Chun Chang,F. Nasroulah +18 more
TL;DR: Ramucirumab plus F OLFIRI significantly improved overall survival compared with placebo plus FOLFIRI as second-line treatment for patients with metastatic colorectal carcinoma and toxic effects were manageable.
Journal ArticleDOI
Pan-Asian adapted ESMO consensus guidelines for the management of patients with metastatic colorectal cancer: a JSMO-ESMO initiative endorsed by CSCO, KACO, MOS, SSO and TOS.
Takayuki Yoshino,Dirk Arnold,Hiroya Taniguchi,George Pentheroudakis,Kentaro Yamazaki,R. Xu,Tae Won Kim,Fuad Ismail,Iain Beehuat Tan,K.-H. Yeh,Axel Grothey,S.Z. Zhang,Joong Bae Ahn,M. Y. Mastura,D. Chong,L.-T. Chen,Scott Kopetz,Takako Eguchi-Nakajima,Hiromichi Ebi,A. Ohtsu,Andrés Cervantes,K. Muro,Josep Tabernero,Hironobu Minami,Fortunato Ciardiello,J.-Y. Douillard +25 more
TL;DR: These guidelines represent the consensus opinions reached by experts in the treatment of patients with mCRC identified by the Presidents of the oncological societies of Japan (JSMO), China, Korea, Malaysia, Singapore, Singapore and Taiwan.
Journal ArticleDOI
TAS-102 monotherapy for pretreated metastatic colorectal cancer: a double-blind, randomised, placebo-controlled phase 2 trial
Takayuki Yoshino,Nobuyuki Mizunuma,Kentaro Yamazaki,Tomohiro Nishina,Yoshito Komatsu,Hideo Baba,Akihito Tsuji,Kensei Yamaguchi,Kei Muro,Naotoshi Sugimoto,Yasushi Tsuji,Toshikazu Moriwaki,Taito Esaki,Chikuma Hamada,Takanori Tanase,Atsushi Ohtsu +15 more
TL;DR: In this article, the authors investigated the efficacy and safety of TAS-102 (35 mg/m 2 given orally twice a day in a 28-day cycle [2-week cycle of 5 days of treatment followed by a 2-day rest period, and then a 14-day period] or placebo; all patients received best supportive care.
Journal ArticleDOI
Randomized phase III study of bevacizumab plus FOLFIRI and bevacizumab plus mFOLFOX6 as first-line treatment for patients with metastatic colorectal cancer (WJOG4407G)
Kentaro Yamazaki,Michitaka Nagase,Hiroshi Tamagawa,Shinya Ueda,Takao Tamura,Kohei Murata,T. Eguchi Nakajima,Eishi Baba,Miho Tsuda,Toshikazu Moriwaki,Taito Esaki,Yasushi Tsuji,K. Muro,Koichi Taira,Tadamichi Denda,Sadao Funai,K. Shinozaki,Hideaki Yamashita,Naotoshi Sugimoto,Tatsuya Okuno,Tomohiro Nishina,M. Umeki,T. Kurimoto,Tetsuji Takayama,Akihito Tsuji,Motoki Yoshida,Ayumu Hosokawa,Yoshihiro Shibata,Koichi Suyama,Masataka Okabe,Kenji Suzuki,Nobuhiko Seki,Kentaro Kawakami,Michihiko Sato,Koshi Fujikawa,Tomonori Hirashima,Takaya Shimura,Keisei Taku,Toshio Otsuji,F. Tamura,Eiji Shinozaki,K. Nakashima,Hiroki Hara,Takahiro Tsushima,M. Ando,Satoshi Morita,Narikazu Boku,Ichinosuke Hyodo +47 more
TL;DR: FOLFIRI plus bevacizumab was non-inferior for PFS, compared with mFOLFOX6 plus beVacIZumab, as the first-line systemic treatment for mCRC.